Clinical Trials · NCT03571516

Safety, Efficacy and Pharmacokinetic Study of Teduglutide in Infants 4 to 12 Months of Age With Short Bowel Syndrome

Name: Safety, Efficacy and Pharmacokinetic Study of Teduglutide in Infants 4 to 12 Months of Age With Short Bowel Syndrome
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 3Teduglutide

Phase: Phase 3
Recruitment status: Completed
Sponsor: Shire
Enrollment: 10
Start date: Aug 2018
Locations: 8 sites, 4 countries
Primary endpoint: Number of Participants Who Achieved At Least 20 Percent (%) Reduction From Baseline in Weight-normalized Parenteral Support (PS) Volume at End of Treatment/Early Termination (EOT/ET)

View Teduglutide compound reference